This memorandum describes the typical entity structures used when launching a new private fund. Although various factors influence the choice of entity structures used for a private fund, this memorandum will discuss the most basic considerations – namely preferences of the fund’s investors and the manager. It should be noted at the outset that different…

Rimon Partner Thomas White joined Bill Banham for The HR Gazette’s recent podcast “Banning Non-complete Clauses.” Tom discussed the recent FTC proposal to ban non-compete clauses, the utilization of ERISA plans to enforce non-competes, and what that could mean for companies and employees. Listen to the podcast here. Learn more about The HR Gazette here. …

On January 23, the Supreme Court surprisingly decided to dismiss as “improvidently granted” the writ of certiorari it had granted in the case In re Grand Jury, No. 21-1397. This one-line dismissal order came after full briefing by the parties, thirteen substantive amicus briefs from various legal and business organizations, and oral argument. The issue…

Given the growth of online access to products and services, including those in banking, who has access to the data collected through the use of such services? Access to and control of data is the centerpiece of several new omnibus privacy laws, such as California’s Privacy Rights Act (CPRA) and similar legislation recently enacted in…

CPRA strengthens consumer protection rights in California – companies in Germany and the EU will have to adjust. In the USA, there is no comprehensive data protection law covering all states. With the new California Privacy Rights Act (CPRA), California has once again strengthened the data protection laws of the California Consumer Privacy Act (CCPA),…

On January 10, 2023 the FDA announced that it has partnered with Health Canada to launch a joint eSTAR pilot. The pilot will allow medical device manufacturers to submit a premarket notice submission to FDA and Health Canada simultaneously. eSTAR initially debuted in 2020 for medical device submissions to FDA’s Center for Devices and Radiological…

As a venture founder, raising funds can accelerate your startup’s growth. But what happens when fundraising efforts begin to dissipate? Rimon Partner Dror Futter outlines the 6 S’s Venture Founders should consider when fundraising has stalled. Read here: Infographic: Fundraising Stalled? Here are the 6 S’s Venture Founders Should be Thinking About Dror Futter focuses…

Rimon attorney Amy Baker sat down with Jeffrey Snyder from the Broadcast Retirement Network to discuss the potential impact of classifying aging as a disease on FDA drug approvals. Watch the interview here. Find out more about the Broadcast Retirement Network here.   Amy Baker is a Partner in Rimon’s Orlando office. Ms. Baker focuses…

Article originally published by The Hill. Republished with permission from publisher. Authored by Rimon attorney, Amy Baker. Attorneys Mark H. Mirkin, Steven Colby, JD, Ph.D. and David Devernoe contributed to the piece.  The Food and Drug Administration (FDA) considers aging to be a natural process. This makes it difficult to get FDA approval for drugs…

The Future Financing Act for Germany comes at the right time. Against the backdrop of a dramatically changing business and political climate, it serves to safeguard economic prosperity by promoting private investment, among other things. The paper marks the beginning of the new legislative process. This paper places particular focus on IPOs and includes a…